The Pharma Crunch: Fewer Resources, Same High Expectations
The pharmaceutical and biotech industries are at a pivotal crossroad. Following years of innovation and rapid growth, the sector is now facing a wave of cost-cutting, restructuring, and hiring freezes. From small biotech startups to big pharma, headlines are filled with news of layoffs, budget cuts, and organizational rationalization.
Despite these shifts, expectations haven’t changed. In fact, they’ve grown. Clinical teams are still expected to meet aggressive trial timelines, deliver quality data, and hit enrollment milestones—often with reduced headcount and tighter budgets.
Sound familiar?
You’re not alone. Across the industry, trial planning and execution teams are being asked to do more with less. But without the right support, this pressure can lead to delays, budget overruns, and missed milestones.
That’s where TA Scan can help.
TA Scan: Your Extension in Trial Planning and Feasibility
When internal resources are limited, clinical teams need more than just tools—they need solutions that accelerate decision-making. TA Scan provides exactly that. Acting as a flexible, data-powered extension of your team, we deliver rapid insights tailored to your protocol, helping you select countries, model enrollment, and identify sites with the capacity to recruit—all with precision and speed. The result? Data-backed decisions that help you navigate complexity, bring more predictability to your timelines, and plan with greater confidence.
Here’s what sets us apart:
✅ Speed – Study-specific insights in 24 hours. Yes, really.
✅ Flexibility – Custom data packages for your protocol, your way.
✅ Value – We guarantee price matching on custom feasibility reports.
✅ Support – Real humans, not chatbots, ready to partner with you.
Case in Point: Supporting a Global Oncology Trial from Start to Strategy
To show you exactly how TA Scan delivers under pressure, let’s walk through a recent real-world example.
A global sponsor was preparing for a first-line treatment trial in esophageal cancer—targeting advanced or metastatic disease in patients with no prior systemic chemotherapy or anti-PD-1/anti-PD-L1 treatment. The protocol was complex, and the sponsor needed support to assess trial feasibility across multiple regions: US, EU, and APAC.
They turned to TA Scan.
Here’s how our team delivered:
- Competitive Landscape Analysis
Delivered a comprehensive view of 1,204 esophageal cancer trials initiated in the past 5 years, including 150 that matched the precise patient profile. Identified a total of 993 competing trials globally, of which 74 running in the US, Germany, and Japan.
- Subpopulation-Specific Benchmarking
Analyzed the trials matching the precise patient profile to model realistic enrollment expectations. Leveraged TA Scan’s historical data to return actual and estimated enrollment rates (patients per site per month) from 79 comparable trials—enabling early-stage protocol assessment and planning confidence.
- Country Strategy Development
Recommended the US, Germany, and Japan as high-potential countries for in-depth feasibility modeling. This selection was based on a blend of TA Scan analytics—trial density, regulatory lag, site/investigator experience—and the sponsor’s internal strategy, including local presence and past performance in these markets.
- Site & Investigator Identification with Diversity Insights
Returned a filtered list of 1,239 sites and 1,000 investigators experienced with similar protocols. Our data package included unbiased site and investigator scoring, and diversity heatmaps to align with inclusive enrollment goals.
- Predictive Enrollment Modeling
Provided predictive enrollment simulation for the selected countries, helping to validate the sponsor’s proposed timelines. Evaluated preliminary site lists using TA Scan’s site capacity algorithms to flag potential bottlenecks and prioritize high-performing, underutilized sites.
The final deliverable? The sponsor received a tailored feasibility package, including competitive trial timelines and benchmarks, country analytics, site lists with capacity and diversity insights, investigator shortlists with detailed scoring, and predictive enrollment projections. All delivered as exportable reports for internal decision-making and stakeholder engagement—enabling the sponsor to stay on track, and plan with confidence.
We Scale When You Can’t
Whether you’re navigating internal resource constraints or racing against external deadlines, TA Scan is designed to help you stay strategic—even when your team is stretched thin.
- You don’t need to build a new team.
- You don’t need to spend weeks wrangling data.
- You just need the right partner!
With TA Scan, you can go from overwhelmed to on track—without burning out your team or blowing your budget.
Ready to Lighten the Load?
Your goals haven’t changed. You still need precision, speed, and smart decisions. Let TA Scan help you get there—with less stress, less guesswork, and fewer people.
👉 Contact us for a demo or request a study-specific feasibility package today.
We’ll deliver results in 24 hours—guaranteed.
Images used under license by https://stock.adobe.com/
Authored by Elke Ydens, Associate Director of Business Solutions, Data Division
Elke Ydens, Associate Director of Business Solutions at Anju’s Data Division, brings over a decade of life sciences experience and a PhD in Biochemistry and Biotechnology from the University of Antwerp. As a Subject Matter Expert in Data Science, she adeptly addresses customer needs, leveraging her background in neuro-immunology and biochemistry. Elke remains dedicated to professional growth, contributing to industry publications, and staying updated on industry trends, while also finding success in extracurricular pursuits, formerly competing in world and European bridge championships, and more recently active in beekeeping and coaching. Connect with Elke on LinkedIn to explore her achievements further.